BioMarin's PALYNZIQ Receives FDA Approval for Adolescent PKU Patients 12 and Older

Key Takeaways

• FDA approved PALYNZIQ for adolescents 12 years and older with phenylketonuria (PKU) in February 2026
• Approval expands treatment access for younger PKU patients who previously had limited therapeutic options
• European approval for the same age group is anticipated later in 2026, potentially broadening global market reach

---

BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PALYNZIQ® (pegvaliase-pqpz) for adolescents 12 years of age and older with phenylketonuria (PKU), marking a significant expansion of treatment options for younger patients with this rare genetic disorder.

Expanding Access to PKU Treatment

The February 2026 approval represents a crucial milestone for BioMarin’s flagship PKU therapy, which was previously available only to adult patients. PKU is a rare inherited disorder affecting approximately 1 in 10,000 to 15,000 newborns in the United States, where patients cannot properly break down the amino acid phenylalanine.

PALYNZIQ works as an enzyme substitution therapy, helping patients metabolize phenylalanine and maintain lower blood phenylalanine levels. High phenylalanine concentrations can lead to intellectual disability, behavioral problems, and other serious health complications if left untreated.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Global Expansion

This age expansion significantly broadens PALYNZIQ’s addressable patient population, potentially increasing BioMarin’s market opportunity in the PKU treatment space. The company reported these developments as part of its first quarter 2026 financial results, highlighting the drug’s continued commercial progress.

BioMarin expects to receive European regulatory approval for adolescents 12 years and older later in 2026, which would further expand the drug’s global reach. The European Medicines Agency (EMA) approval would provide access to PKU patients across the European Union, representing another substantial market opportunity.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Clinical Significance

For adolescent PKU patients, PALYNZIQ offers an alternative to strict dietary restrictions that have traditionally been the primary management approach. The therapy’s availability for younger patients addresses a critical unmet medical need, as maintaining dietary compliance becomes increasingly challenging during adolescence.

The approval was based on clinical data demonstrating PALYNZIQ’s safety and efficacy in the adolescent population, though specific trial results were not detailed in the company’s announcement.

---

Frequently Asked Questions

What does this FDA approval mean for adolescent PKU patients?

The approval means adolescents 12 and older with PKU now have access to PALYNZIQ as a treatment option, potentially reducing their reliance on strict dietary restrictions and helping them maintain lower blood phenylalanine levels.

When will PALYNZIQ be available for adolescents in Europe?

BioMarin expects European approval for adolescents 12 years and older with PKU to occur sometime in 2026, though a specific timeline has not been announced.

How does PALYNZIQ work compared to traditional PKU treatments?

Unlike traditional PKU management that relies primarily on strict low-protein diets, PALYNZIQ is an enzyme substitution therapy that helps patients break down phenylalanine, potentially offering more flexibility in dietary choices.

Related coverage

• TGA Australia drug approval pharmaceutical: what the regulator is
• NMPA China FDA Drug Approval: 2026 Pathways, Timelines & Impact
• Datroway Approved: A New Hope for Metastatic TNBC Patients